Therapeutics Development Network

Through efficient study design, optimized clinical trial execution, and high-quality data, the Therapeutics Development Network (TDN) helps speed the delivery of new and better therapies to people with cystic fibrosis.

Therapeutics Development Network investigators and research staff work every day to promote quality, safety, and efficiency in cystic fibrosis clinical research and help speed the delivery of new and better therapies to people with CF.

Effective clinical development plans and good study design can save sponsors and investigators time and money, leading to faster development of potential new therapies for people with cystic fibrosis.

The Therapeutics Development Network's (TDN) Protocol Review Process ensures optimum safety and quality in cystic fibrosis clinical trial protocols.

The Clinical Research Executive Committee (CREC) assesses how a specific protocol fits within the overall clinical research priorities of the cystic fibrosis community and assigns it a rating.

The Therapeutics Development Network includes 80 clinical research centers, called Therapeutics Development Centers.

The primary responsibility of the independent Data Safety Monitoring Board is to protect the safety and welfare of people who participate in clinical trials approved by the Therapeutics Development Network.

The strength of the Therapeutics Development Network Coordinating Center lies in our unparalleled experience in setting up and managing cystic fibrosis studies and our intimate knowledge of the CF research community.

The Therapeutics Development Network Coordinating Center Biostatistics and Clinical Data Management team has extensive expertise in the support of both controlled clinical trials and observational studies. We offer full statistical and data management support -- from planning to implementation to reporting.

The Therapeutics Development Network Coordinating Center can provide coverage and coordination for the review and reporting of serious adverse events that may occur during the course of cystic fibrosis clinical studies.

The Therapeutics Development Network Coordinating Center partners with the Investigational Drug Service at Seattle Children's Hospital to provide pharmacy-related support for multi-center CF clinical studies.